Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a leading medical device company dedicated to developing innovative solutions for the interventional treatment of vascular thrombi and emboli. The company's mission centers on improving the lives of patients suffering from venous and other related diseases through the design and production of advanced medical devices.
Inari Medical's product portfolio includes several key devices:
- ClotTriever: Designed for the removal of clots from peripheral blood vessels, primarily treating patients with deep vein thrombosis (DVT).
- FlowTriever System: Used for the treatment of pulmonary embolism (PE).
- InThrill System: Aimed at treating small vessel thrombosis.
- LimFlow System: Another innovative solution recently added to their portfolio through acquisition.
The company operates extensively within the United States but also generates significant revenue from international markets. Inari Medical's dedication to clinical research and patient education is evident in their continuous efforts to generate high-quality clinical data to support their products.
In recent news, Inari Medical announced the PEERLESS II RCT, a major clinical study involving up to 1,200 patients. This study aims to influence global guidelines for treating intermediate-risk PE patients. Inari's fourth-quarter financial results showed a substantial revenue increase, driven by the strong adoption of their procedures, new product launches, and global commercial expansion. The company reported $132.1 million in revenue for Q4 2023, marking a 22.6% increase year-over-year.
Additionally, Inari Medical has undertaken significant legal action to protect its intellectual property. The company filed a patent infringement lawsuit against Imperative Care, Inc. and Truvic Medical, Inc., seeking injunctive relief and damages for infringement on eight of its patents.
Guided by principles such as putting patients first and fostering innovation, Inari Medical continues to advance its mission of establishing its treatments as the standard of care for venous thromboembolism and beyond.
Inari Medical, Inc. (NASDAQ: NARI) announced positive results from the FLAME study for high-risk pulmonary embolism (PE) during the 2023 ACC conference. This is the largest prospective study of interventional treatment in this patient group, historically facing a 25-50% mortality rate. The study showed a mortality rate of just 1.9% in patients treated with FlowTriever, a 90% reduction compared to the 29.5% rate in the control group. The trial's early termination highlights the significant effectiveness of FlowTriever, suggesting it may change clinical practice guidelines and improve survival rates for high-risk PE patients.
Inari Medical reported a strong financial performance for Q4 2022, generating $107.8 million in revenue, marking a 30% year-over-year increase. For the full year, revenue reached $383.5 million, a 38% increase compared to 2021. The net loss for Q4 was $5.8 million with a loss per share of $0.11. Operating expenses rose to $100.5 million, up from $73.2 million in Q4 2021, driven by increased headcount for expansion. Despite a decrease in gross margin, now at 87.8%, the company reaffirmed its 2023 revenue guidance of $470-480 million.
Inari Medical, Inc. (NASDAQ: NARI) announced the release date for its fourth quarter and full year 2022 financial results, set for February 27, 2023. Following the release, Inari will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss financial outcomes and recent developments. Interested parties can access the live call via phone or webcast through the Inari investor relations website. The company emphasizes its commitment to innovating solutions for unmet health needs and aims to establish its treatments as the standard of care for venous thromboembolism.
Inari Medical, Inc. (NASDAQ: NARI), a leading medical device company, will participate virtually in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 14, 2023. The company is dedicated to transforming patient care through innovative solutions for venous diseases and beyond. Inari’s ethos emphasizes patient-focused principles and a commitment to improving lives. They strive to establish their treatments as the standard of care for venous thromboembolism. For inquiries, investors can contact Caroline Corner at ICR Westwicke.
Inari Medical (NASDAQ: NARI) has announced the enrollment of the first patient in the DEFIANCE trial, a pivotal randomized controlled trial comparing the ClotTriever System with traditional anticoagulation for treating iliofemoral deep vein thrombosis (DVT). The trial aims to enroll 300 patients across 60 centers globally. Esteemed medical professionals lead the trial, which seeks to establish stronger evidence for DVT treatment methods. Inari has a strong commitment to advancing care for venous thromboembolism through ongoing clinical research.
Inari Medical, Inc. (NASDAQ: NARI) reported preliminary unaudited revenues for Q4 2022 between $107.0 million and $108.0 million, marking a 29% year-over-year increase, and full-year revenues expected between $382.7 million and $383.7 million, representing a 38% increase from 2021. The company projected 2023 revenue between $470 million and $480 million, reflecting a growth of approximately 23% to 25%. The results are preliminary and subject to audit revisions.
Inari Medical, Inc. (NASDAQ: NARI) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 11th at 2:15 PM PT. The management team's presentation will be available for 30 days via a live audio webcast on the company's website.
Inari focuses on medical devices aimed at treating venous diseases. Their products include the ClotTriever and FlowTriever systems, both 510(k)-cleared by the FDA, designed for non-surgical removal of clots in patients with conditions like deep vein thrombosis and pulmonary embolism.
Inari Medical, Inc. (NASDAQ: NARI), a company dedicated to developing medical devices for venous diseases, announced its participation in the Canaccord Genuity MedTech Forum on November 17, 2022, at the Westin NY Grand Central Hotel. The company specializes in catheter-based mechanical thrombectomy devices, including the ClotTriever and FlowTriever systems, designed for non-surgical removal of clots from blood vessels. Both products are FDA 510(k)-cleared and CE marked, targeting deep vein thrombosis and pulmonary embolism.
Inari Medical, Inc. (NASDAQ: NARI) reported third-quarter 2022 revenue of $96.2 million, a 32% increase from the same quarter in 2021. The growth is attributed to U.S. commercial expansion, increased procedure adoption, and the launch of two new products, Protrieve and InThrill. Despite a net loss of $10.2 million for the quarter, the company ended with $319.2 million in cash and investments. Inari has raised its full-year revenue guidance to a range of $373 million to $375 million.
Inari Medical, Inc. (NASDAQ: NARI) announced positive results from the 500-patient CLOUT registry, confirming the ClotTriever system's effectiveness for treating deep vein thrombosis (DVT). Over 90% of patients achieved complete thrombus extraction with only one serious device-related adverse event. The analysis also revealed that ClotTriever had nearly double the thrombus clearance compared to standard treatment methods, along with a 13% reduction in post-thrombotic syndrome. Inari aims to establish ClotTriever as a standard of care for DVT and pulmonary embolism (PE) patients.
FAQ
What is the current stock price of Inari Medical (NARI)?
What is the market cap of Inari Medical (NARI)?
What does Inari Medical, Inc. specialize in?
What are the key products in Inari Medical's portfolio?
Where does Inari Medical generate most of its revenue?
What recent clinical study has Inari Medical announced?
How did Inari Medical perform financially in the fourth quarter of 2023?
What is Inari Medical's approach to innovation?
Who should investors contact for more information?
What legal actions has Inari Medical recently taken?
What are Inari Medical's guiding principles?
How can interested parties access Inari Medical's live events?
